预约演示
更新于：2026-03-17
Cefcamate Pivoxil Hydrochloride
盐酸头孢卡品酯
更新于：2026-03-17
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H32ClN5O9S2 |
InChIKeyLUXIJPQYUCFVAL-XRLCNELCSA-N |
CAS号147816-24-8 |
关联
22
项与 盐酸头孢卡品酯 相关的临床试验CTR20254752
盐酸头孢卡品酯颗粒在健康受试者中空腹和餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
CTR20254611
盐酸头孢卡品酯颗粒健康人体生物等效性研究
CTR20252783
盐酸头孢卡品酯颗粒（50mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 盐酸头孢卡品酯 相关的临床结果
登录后查看更多信息
100 项与 盐酸头孢卡品酯 相关的转化医学
登录后查看更多信息
100 项与 盐酸头孢卡品酯 相关的专利（医药）
登录后查看更多信息
117
项与 盐酸头孢卡品酯 相关的文献（医药）2025-10-01Taiwan Journal of Ophthalmology
Therapeutic outcomes of oral cefcapene in meibomitis-related keratoconjunctivitis: A Propensity-matched cohort study
Article
作者: Park, Ella (Seo Yeon) ; Ahn, Hyunmin ; Seo, Kyoung Yul
Abstract::
PURPOSE::
The purpose of the study was to evaluate the clinical characteristics and therapeutic response in patients with meibomitis-related keratoconjunctivitis (MRKC) who were treated with oral cefcapene pivoxil hydrochloride hydrate, and to determine factors associated with favorable outcomes.
MATERIALS AND METHODS::
A retrospective analysis was conducted on 62 patients with MRKC, including 31 patients who received a 14-day course of oral cefcapene (100 mg three times daily) in combination with standard warm compression and lid hygiene. These patients were 1:1 propensity score–matched with 31 controls who underwent warm compression and lid hygiene, based on age, sex, meibomian gland expressibility, and meibum quality. Baseline characteristics and posttreatment outcomes – including corneal staining score (CSS) and ocular surface disease index (OSDI) – were compared between the groups.
RESULTS::
One month after treatment, mean CSS was significantly lower in the cefcapene group (0.55 ± 0.65) compared with controls (0.86 ± 0.44,
P
= 0.032*). The cefcapene group also showed higher rates of complete corneal staining resolution (CSS = 0) and greater OSDI improvement, although these outcomes did not reach statistical significance.
CONCLUSION::
Adjunctive use of short-term oral cefcapene therapy alongside standard eyelid hygiene measures resulted in a significant reduction in CSSs in patients with MRKC. However, this reduction was not accompanied by a statistically significant improvement in subjective symptoms.
2024-12-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Sensitive quantification of fibroblast activation protein and high-throughput screening for inhibition by FDA-approved compounds
Article
作者: Staňurová, Jana ; Šácha, Pavel ; Šimková, Adéla ; Kryštůfek, Robin ; Vaníčková, Zdislava ; Bušek, Petr ; Čermáková, Kateřina ; Wichterle, Filip ; Konvalinka, Jan
Fibroblast activation protein (FAP) has been extensively studied as a cancer biomarker for decades. Recently, small-molecule FAP inhibitors have been widely adopted as a targeting moiety of experimental theranostic radiotracers. Here we present a fast qPCR-based analytical method allowing FAP inhibition screening in a high-throughput regime. To identify clinically relevant compounds that might interfere with FAP-targeted approaches, we focused on a library of FDA-approved drugs. Using the DNA-linked Inhibitor Antibody Assay (DIANA), we tested a library of 2667 compounds within just a few hours and identified numerous FDA-approved drugs as novel FAP inhibitors. Among these, prodrugs of cephalosporin antibiotics and reverse transcriptase inhibitors, along with one elastase inhibitor, were the most potent FAP inhibitors in our dataset. In addition, by employing FAP DIANA in the quantification mode, we were able to determine FAP concentrations in human plasma samples. Together, our work expands the repertoire of FAP inhibitors, analyzes the potential interference of co-administered drugs with FAP-targeting strategies, and presents a sensitive and low-consumption ELISA alternative for FAP quantification with a detection limit of 50 pg/ml.
2024-10-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Homology of Escherichia coli isolated from urine and vagina and their antimicrobial susceptibility in postmenopausal women with recurrent cystitis
Article
作者: Hirakawa, Hidetada ; Wada, Koichiro ; Araki, Motoo ; Sadahira, Takuya ; Ishii, Ayano ; Sekito, Takanori
Uropathogenic Escherichia coli (UPEC) is a typical cystitis-causing organism that can migrate from the vagina to the bladder and cause recurrent cystitis (RC). Few reports have compared the characteristics of urinary and vaginal UPEC in patients with RC. We carried out molecular biological analyses of Escherichia coli (E. coli) strains and their antimicrobial susceptibility to assess the association between urinary and vaginally UPEC. We included E. coli isolated from urinary and vaginal samples at the onset of cystitis in postmenopausal women with RC between 2014 and 2019 in our hospital. Pulsed-field gel electrophoresis (PFGE) was performed using a restriction enzyme (Xba I). These sequences were compared with 17 antimicrobial susceptibilities determined by a micro-liquid dilution method. Multilocus sequence typing (MLST) and classification of extended-spectrum β-lactamase (ESBL) genotypes by multiplex polymerase chain reaction (PCR) were performed on ESBL-producing E. coli. We analyzed 14 specimens (each seven urine and vaginal) from seven patients in total. On PFGE, the similarity of urinary and vaginal E. coli per patient ranged from 89.5 to 100 %, including four patients with 100 % matches. MLST demonstrated that 29 % (4/14 specimens) were strain sequence type 131. Two specimens contained ESBL-producing strains and identified the CTX-M-27 genotype for each specimen. For each patient, antimicrobial susceptibilities between urinary and vaginal E. coli were mostly identical. Thus, urinary- and vaginally-derived E. coli were identical in postmenopausal women with RC. Management targeting both urinary and vaginal UPEC is essential for RC, indicating the importance of a vagina-targeted approach.
100 项与 盐酸头孢卡品酯 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌感染 | 中国 | 2010-12-31 | |
| 急性支气管炎 | 日本 | 1997-04-22 | |
| 胆管炎 | 日本 | 1997-04-22 | |
| 胆囊炎 | 日本 | 1997-04-22 | |
| 膀胱炎 | 日本 | 1997-04-22 | |
| 泪囊炎 | 日本 | 1997-04-22 | |
| 睑腺炎 | 日本 | 1997-04-22 | |
| 子宫内感染 | 日本 | 1997-04-22 | |
| 颌骨骨炎 | 日本 | 1997-04-22 | |
| 喉炎 | 日本 | 1997-04-22 | |
| 淋巴结炎 | 日本 | 1997-04-22 | |
| 淋巴管炎 | 日本 | 1997-04-22 | |
| 乳腺炎 | 日本 | 1997-04-22 | |
| 睑板腺炎 | 日本 | 1997-04-22 | |
| 外耳炎 | 日本 | 1997-04-22 | |
| 中耳炎 | 日本 | 1997-04-22 | |
| 盆腔炎 | 日本 | 1997-04-22 | |
| 冠周炎 | 日本 | 1997-04-22 | |
| 牙周炎 | 日本 | 1997-04-22 | |
| 咽炎 | 日本 | 1997-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用